Nrx pharmaceuticals announces new finding from zyesami™ (aviptadil) phase 2b/3 clinical trial demonstrating clinically significant relief from respiratory distress in critical covid-19

Radnor, pa., aug. 30, 2021 /prnewswire/ -- nrx pharmaceuticals (nrx) (nasdaq: nrxp) announced an additional finding in its phase 2b/3 clinical trial investigating zyesami™ (aviptadil) for the treatment of patients with acute respiratory failure due to critical covid-19.

NRXP Ratings Summary

NRXP Quant Ranking